GLP-1 Medications and Women's Weight Loss: What the Latest Research Tells Us

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Please consult a qualified healthcare provider before starting any new medication or treatment program.

If you've been hearing a lot about GLP-1 medications lately, you're not alone. Semaglutide and tirzepatide have become household names — and for good reason. For women navigating weight gain related to hormonal shifts, metabolic changes, or conditions like PCOS, these medications are changing what's possible. But with so much noise out there, it can be hard to separate real science from hype.

Here's what the latest clinical research actually says — and what it means for you.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces to regulate blood sugar and appetite. GLP-1 receptor agonists — medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — mimic this hormone, helping you feel fuller sooner, reducing cravings, and supporting steadier blood sugar levels.

They are prescription medications, used under medical supervision, and are not appropriate for everyone. The right candidate, the right dose, and ongoing monitoring all matter enormously.

What New Research Is Showing for Women Specifically

The clinical picture for women is genuinely exciting, and the data from 2024 and 2025 is more specific than ever.

Women tend to see strong results with tirzepatide. A post-hoc analysis of the SURMOUNT clinical trials (Obesity, 2025) found significant body weight reductions with tirzepatide versus placebo across all reproductive stages — 26% mean reduction in premenopausal women, 23% in perimenopausal, and 23% in postmenopausal women. That is a clinically significant outcome, not a rounding error.

PCOS responds well. A study published in 2026 found that women with polycystic ovary syndrome achieved a mean weight loss of 18.81% at 10 months on tirzepatide — comparable to women without PCOS — and 96.6% lost at least 5% of their total body weight. For women who have struggled with PCOS-related weight gain for years, this is meaningful.

Menopausal status matters less than you might think. Data from the OASIS 4 phase 3 trial, presented at ObesityWeek 2025, showed that oral semaglutide was effective across all menopausal stages. Pre-menopausal women lost an average of 18.2% of body weight, perimenopausal women lost 15%, and postmenopausal women lost 15.7% over 64 weeks. The gap is smaller than many patients expect. (Note: these figures are from a Novo Nordisk conference press release; a peer-reviewed publication of this specific subgroup analysis was not available at time of writing.)

Combining GLP-1s with hormone therapy may enhance results. A Mayo Clinic study presented at ENDO 2025 found that postmenopausal women using menopausal hormone therapy alongside tirzepatide lost an average of 17% of body weight, compared to 14% for those on tirzepatide alone. Nearly half of the hormone therapy group achieved 20% or more weight loss. This combination approach is an active area of research and one we follow closely at OptimaVida. (Note: this finding is from a conference abstract; a peer-reviewed publication was not available at time of writing.)

Long-term results are holding. The SELECT trial demonstrated sustained weight loss averaging 10.2% at four years on semaglutide. Weight loss medications are not a quick fix — they work best as part of a long-term, medically supervised plan.

What These Medications Don't Replace

GLP-1 medications are a powerful tool, not a standalone solution. They work best when paired with nutrition support, movement, sleep attention, and regular clinical follow-up. They also don't address the underlying hormonal contributors to weight gain that many women in their 30s, 40s, and 50s experience — which is why a comprehensive approach matters.

At OptimaVida, we evaluate each patient's full picture: hormones, metabolic markers, lifestyle, and goals. GLP-1 medications may be one part of that plan. They may not be the right fit for everyone, and we'll tell you honestly either way.

Common Questions We Hear

Are these medications safe long-term? Research is ongoing, but existing multi-year data (including the SELECT trial) shows continued safety and tolerability for most patients. Side effects — primarily nausea, especially early on — are real and manageable with proper dose titration. Your provider should walk you through what to expect.

What's the difference between semaglutide and tirzepatide? Tirzepatide acts on two hormonal pathways (GLP-1 and GIP), while semaglutide targets GLP-1 alone. A 2025 network meta-analysis of 28 randomized controlled trials found that tirzepatide produced greater mean weight loss — about 6.1 percentage points more than semaglutide. Individual response still varies, and cost and availability factor in too.

Do I need to stay on them forever? Not necessarily, but stopping often leads to some weight regain. Your provider can help you think through a long-term strategy rather than treating this as a finite course.

When to See a Professional

If you're struggling with weight despite consistent effort — especially if you've noticed changes tied to perimenopause, thyroid shifts, PCOS, or metabolic syndrome — it is worth having a real clinical conversation. Self-guided approaches and over-the-counter supplements are not the same as a medically supervised plan built around your specific labs, history, and goals.

Please don't rely on this article alone to make any medication decisions. Reach out to a licensed provider who can evaluate whether a GLP-1 medication is appropriate for you.

Ready to find out if GLP-1 medications are right for you? Book a free consult with Ana Noriega, APRN — no insurance needed, available across Florida. A real conversation, no rushed visits, with a board-certified nurse practitioner who has 20+ years of clinical experience.

This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any treatment.

References

1. Tchang BG, Ciudin Mihai A, Stefanski A, et al. "Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program." Obesity. 2025 May;33(5):851–860. doi: https://doi.org/10.1002/oby.24254

2. Bednarz K, et al. "Weight loss outcomes with tirzepatide in women with and without polycystic ovary syndrome." PMC / PubMed. 2026. PMID: 42634795. Available at: https://pubmed.ncbi.nlm.nih.gov/42634795/

3. Novo Nordisk. "Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors." Press release; November 5, 2025. Available at: https://www.prnewswire.com/news-releases/novo-nordisk-presents-four-new-analyses-on-oral-semaglutide-25-mg-wegovy-in-a-pill-at-obesityweek-2025-302605329.html

4. Lincoff AM, et al. (SELECT trial investigators). "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial." Nature Medicine. 2024. doi: https://doi.org/10.1038/s41591-024-02996-7

5. Bernardi JC, Cavalcante DVS, Huntermann R, et al. "Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide." Journal of Diabetes. 2026 Feb 10;18(2):e70192. doi: https://doi.org/10.1111/1753-0407.70192. PMC12887578.